Abstract
A model immunosuppressant BCS Class II drug was selected for the work to assess the formulation variables on the release rate using design of experiment (DoE) - Stat-Ease software. Surface solid dispersion was prepared with dichloromethane (DCM) and ethanol mixture (4:1), and converted to tablet by adsorption on a neutral carrier. Different batches were prepared with DoE full factorial design. The concentrations of Polaxamer 188, Kollidon CL and Magnesium stearate were found to be the critical factors affecting the performance of the tablets. These parameters were selected as the independent variables in DoE and the formulated batches were evaluated for their percentage release at 120 minutes. The actual and predicted plots fall close to the line. ANOVA (partial sum squares-type-III) reveals the model with F-value of 1417.12 which implies significant. The optimized batch with dissolution profile of 99.6% falls close to the innovator product 98.8%.
Keywords: ANOVA, BCS class II drug, design of experiment, F-value, immunosuppressant, R2 value.
Current Drug Delivery
Title:Assessment of Formulation Factors on the Release Behaviour of BCS Class II Drug from Tablet Dosage form Using DoE
Volume: 11 Issue: 4
Author(s): Urmila Sri Syamala, Raman Suresh Kumar, Tambi Anuj Pushkarajan and Kuppuswamy Gowthamarajan
Affiliation:
Keywords: ANOVA, BCS class II drug, design of experiment, F-value, immunosuppressant, R2 value.
Abstract: A model immunosuppressant BCS Class II drug was selected for the work to assess the formulation variables on the release rate using design of experiment (DoE) - Stat-Ease software. Surface solid dispersion was prepared with dichloromethane (DCM) and ethanol mixture (4:1), and converted to tablet by adsorption on a neutral carrier. Different batches were prepared with DoE full factorial design. The concentrations of Polaxamer 188, Kollidon CL and Magnesium stearate were found to be the critical factors affecting the performance of the tablets. These parameters were selected as the independent variables in DoE and the formulated batches were evaluated for their percentage release at 120 minutes. The actual and predicted plots fall close to the line. ANOVA (partial sum squares-type-III) reveals the model with F-value of 1417.12 which implies significant. The optimized batch with dissolution profile of 99.6% falls close to the innovator product 98.8%.
Export Options
About this article
Cite this article as:
Syamala Sri Urmila, Kumar Suresh Raman, Pushkarajan Anuj Tambi and Gowthamarajan Kuppuswamy, Assessment of Formulation Factors on the Release Behaviour of BCS Class II Drug from Tablet Dosage form Using DoE, Current Drug Delivery 2014; 11 (4) . https://dx.doi.org/10.2174/156720181104140626121252
DOI https://dx.doi.org/10.2174/156720181104140626121252 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers